Value of contrast-enhanced ultrasonography in evaluating blood perfusion characteristics of pulmonary adenocarcinoma and squamous cell carcinoma

doi:10.3877/cma.j.issn.1672-6448.2023.11.012

Abstract

Abstract:

Objective

To compare and analyze the enhancement characteristics of pulmonary adenocarcinoma (ADC) and squamous cell carcinoma (SCC) on contrast-enhanced ultrasonography (CEUS), and to investigate the value of CEUS in evaluating the differences in blood perfusion characteristics of ADC and SCC.

Methods

A total of 54 patients with pulmonary ADC and 46 patients with SCC confirmed by pathology at the Second Hospital of Shanxi Medical University from October 2017 to December 2021 were retrospectively selected. The chi-square test was used to compare the CEUS characteristics between pulmonary ADC and SCC, including the enhancement phase (early pulmonary-arterial [PA] pattern of enhancement, delayed bronchial-arterial [BA] pattern of enhancement), enhancement pattern (basal dendritic enhancement, chaotic vascular enhancement), and peak pattern of CEUS (homogeneous enhancement, inhomogeneous enhancement).

Results

There were some differences in the enhancement characteristics between ADC and SCC, with more ADC (70.4%, 38/54) than SCC (45.7%, 21/46) cases showing PA pattern of enhancement in the enhancement phase; more ADC (20.4%, 11/54) than SCC (4.3%, 2/46) cases showing basal dendritic enhancement in the enhancement pattern; and more SCC (67.4%, 31/46) than ADC (16.7%, 9/54) cases showing inhomogeneous enhancement in the peak pattern; the differences were statistically significant χ²=6.274, 5.638, and 26.630; P=0.012, =0.018, and <0.001, respectively).

Conclusion

There are some differences in enhancement characteristics of CEUS between ADC and SCC. CEUS can evaluate the differences in blood perfusion characteristics between them, and has potential clinical value in the selection of treatment plan and differential diagnosis of ADC and SCC.

Key words: Ultrasonography, Contrast medium, Non-small cell lung carcinoma, Lung adenocarcinoma, Squamous cell carcinoma

Xin Zhao, Lei Hao, Lijing Zhu, Jizheng Tu, Bojuan Wang, Kai Zhang, Xinghua Wang. Value of contrast-enhanced ultrasonography in evaluating blood perfusion characteristics of pulmonary adenocarcinoma and squamous cell carcinoma[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(11): 1181-1185.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://chaosheng.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1672-6448.2023.11.012

https://chaosheng.cma-cmc.com.cn/EN/Y2023/V20/I11/1181

Figures/Tables 6

References 18

1	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2	原发性肺癌诊疗规范(2018年版) [J]. 肿瘤综合治疗电子杂志, 2019, 5(3): 100-120.
3	Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer [J]. Nature, 2018, 553(7689): 446-454.
4	郭西源, 郝磊, 朱丽静, 等. 超声造影鉴别诊断周围型肺局灶性病变的临床价值 [J]. 临床超声医学杂志, 2020, 22(11): 866-868.
5	朱丽静, 王兴华. 超声造影定量参数对肺部良恶性病变鉴别诊断的研究 [J]. 中国临床医学影像杂志, 2020, 31(1): 34-37.
6	郭西源, 朱丽静, 土继政, 等. 超声造影与增强CT对周围型肺局灶性病变诊断价值的对比研究 [J]. 中国临床医学影像杂志, 2021, 32(11): 799-802.
7	Safai Zadeh E, Gorg C, Prosch H, et al. WFUMB technological review: how to perform contrast-enhanced ultrasound of the lung [J]. Ultrasound Med Biol, 2022, 48(4): 598-616.
8	Wang W, Liu H, Li G. What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients [J]. Front Endocrinol (Lausanne), 2022, 13: 947443.
9	董伟华, 肖湘生, 李惠民, 等. 支气管动脉和肺动脉多层螺旋CT血管造影对肺癌血供的研究 [J]. 中华放射学杂志, 2003, 37(7): 612-614.
10	Kuczynski EA, Vermeulen PB, Pezzella F, et al. Vessel co-option in cancer [J]. Nat Rev Clin Oncol, 2019, 16(8): 469-493.
11	Findeisen H, Trenker C, Figiel J, et al. Vascularization of primary, peripheral lung carcinoma in CEUS - a retrospective study (n = 89 Patients) [J]. Ultraschall Med, 2019, 40(5): 603-608.
12	Li Q, Nie F, Yang D, et al. Contrast-enhanced ultrasound (CEUS)—A new tool for evaluating blood supply in primary peripheral lung cancer [J]. Clin Hemorheol Microcirc, 2023, 83(1): 61-68.
13	Nguyen-kim TD, Frauenfelder T, Strobel K, et al. Assessment of bronchial and pulmonary blood supply in non-small cell lung cancer subtypes using computed tomography perfusion [J]. Invest Radiol, 2015, 50(3): 179-186.
14	Daum S, Hagen H, Naismith E, et al. The role of anti-angiogenesis in the treatment landscape of non-small cell lung cancer - new combinational approaches and strategies of neovessel inhibition [J]. Front Cell Dev Biol, 2020, 8: 610903.
15	李相生, 张挽时, 熊明辉, 等. 周围型肺鳞癌与周围型肺腺癌的螺旋CT动态增强对照 [J]. 中华肿瘤杂志, 2006, 28(1): 70-73.
16	Koenigkam Santos M, Muley T, Warth A, et al. Morphological computed tomography features of surgically resectable pulmonary squamous cell carcinomas: impact on prognosis and comparison with adenocarcinomas [J]. Eur J Radiol, 2014, 83(7): 1275-1281.
17	陈亚男, 陈武飞, 滑炎卿. 肺结节倍增时间的CT研究进展 [J]. 中华解剖与临床杂志, 2017, 22(6): 522-527.
18	中国临床肿瘤学会血管靶向治疗专家委员会, 中国临床肿瘤学会非小细胞肺癌专家委员会, 中国临床肿瘤学会非小细胞肺癌抗血管生成药物治疗专家组. 晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2020版) [J]. 中华肿瘤杂志, 2020, 42(12): 1063-1077.

组别	例数	年龄（岁，）	病灶最大径（cm，）	男/女（例）
肺腺癌组	54	64.3±9.9	5.31±2.57	36/18
肺鳞癌组	46	71.2±9.6	6.88±2.59	45/1
统计值		t=-3.542	t=-3.032	χ²=15.671
P值		0.001	0.003	<0.001

组别	例数	年龄（岁，）	病灶最大径（cm，）	男/女（例）
肺腺癌组	54	64.3±9.9	5.31±2.57	36/18
肺鳞癌组	46	71.2±9.6	6.88±2.59	45/1
统计值		t=-3.542	t=-3.032	χ²=15.671
P值		0.001	0.003	<0.001

组别	例数	增强时相		增强模式		达峰模式
组别	例数	肺动脉增强	支气管动脉增强	基底树枝型	杂乱血管型	不均匀型	均匀型
肺腺癌组	54	38（70.4）	16（29.6）	11（20.4）	43（79.6）	9（16.7）	45（83.3）
肺鳞癌组	46	21（45.7）	25（54.3）	2（4.3）	44（95.7）	31（67.4）	15（32.6）
χ²值		6.274		5.638		26.630
P值		0.012		0.018		<0.001

组别	例数	增强时相		增强模式		达峰模式
组别	例数	肺动脉增强	支气管动脉增强	基底树枝型	杂乱血管型	不均匀型	均匀型
肺腺癌组	54	38（70.4）	16（29.6）	11（20.4）	43（79.6）	9（16.7）	45（83.3）
肺鳞癌组	46	21（45.7）	25（54.3）	2（4.3）	44（95.7）	31（67.4）	15（32.6）
χ²值		6.274		5.638		26.630
P值		0.012		0.018		<0.001

组别	例数	不均匀型	均匀型	P值
A组				-
肺腺癌	11	0	11（100）
肺鳞癌	1	0	1（100）
B组				0.013
肺腺癌	14	1（7.1）	13（92.9）
肺鳞癌	13	7（53.8）	6（46.2）
C组				0.060
肺腺癌	18	6（33.3）	12（66.7）
肺鳞癌	12	9（75.0）	3（25.0）
D组				0.007
肺腺癌	11	2（18.2）	9（81.8）
肺鳞癌	20	15（75.0）	5（25.0）

Please choose a citation manager

Content to export